Evidence map›Paper›PMID 37303659›Full record

ArticleAmerican journal of translational research2023

Comparison of the clinical efficacy of donafinil and lenvatinib in the treatment of intermediate and advanced hepatocellular carcinoma.

Qinzhen He, Mengguang Guo, Yanhong Ya, Jinli Huang, Aiqiu Liu, Wexiang Jing

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Qinzhen HeOncology Department, No. 1 People's Hospital of Hechi Hechi 546300, Guangxi, China.
Mengguang GuoOncology Department, No. 1 People's Hospital of Hechi Hechi 546300, Guangxi, China.
Yanhong YaOncology Department, No. 1 People's Hospital of Hechi Hechi 546300, Guangxi, China.
Jinli HuangOncology Department, No. 1 People's Hospital of Hechi Hechi 546300, Guangxi, China.
Aiqiu LiuOncology Department, No. 1 People's Hospital of Hechi Hechi 546300, Guangxi, China.
Wexiang JingSurgery Department, No. 1 People's Hospital of Hechi Hechi 546300, Guangxi, China.
Hechi University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare the therapeutic effects of donafinil and lenvatinib in the treatment of patients with intermediate--advanced hepatocellular carcinoma (HCC).

methodsA total of 100 patients with intermediate--advanced HCC who received donafinib or lenvatinib treatment in Hechi First People's Hospital, Hechi People's Hospital, the Second Affiliated Hospital of Guangxi University of Science and Technology, and other centers from January 2021 to June 2022 were retrospectively analyzed. The patients were classified into a donafinil group (n=50) and a lenvatinib group (n=50) according to the treatment method. The therapeutic effects and adverse reactions of the two groups were compared, as well as the changes in alpha-fetoprotein (AFP), Golgi glycoprotein 73 (GP-73), and glypican-3 (GPC3) before and after treatment.

resultsThe objective remission rate in the lenvatinib group was less than that in the donafenib group (20% VS 32%,

conclusionBoth donafenib and lenvatinib can effectively treat patients with middle and advanced hepatocellular carcinoma, and the local control rate of donafenib is higher than that of lenvatinib. The treatment of intermediate--advanced hepatocellular carcinoma patients with donafinib has better clinical efficacy than levatinib, which can effectively reduce the severity of patients' disease and prolong their survival time.

Indexed as

donafenilHepatocellular carcinomalenvatinib

Identifiers

PMID37303659
PMCPMC10250965
OpenAlexW4380291890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.